Drug interactions with triptans: Which are clinically significant?

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 949-957

  Rolan, Paul E ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; BUTORPHANOL; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; FLUNARIZINE; FLUOXETINE; FLUVOXAMINE; FROVATRIPTAN; HYPERICUM PERFORATUM EXTRACT; METHYSERGIDE; METOCLOPRAMIDE; METOPROLOL; MOCLOBEMIDE; NADOLOL; NAPROXEN PLUS SUMATRIPTAN SUCCINATE; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIZOTIFEN; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; VERAPAMIL; ZOLMITRIPTAN;

ADVERSE OUTCOME; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; LIFESTYLE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; ERGOT ALKALOIDS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGENTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; TRYPTAMINES;

EID: 84873433017     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0002-5     Document Type: Review

References (45)

1. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology. 1960;10:107-11.
2. Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008;48:685-7.
3. Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia. 1997;17:639-46.
4. Usha Rani P, Naidu MUR, Ramesh Kumar Rao T, et al. Sumatriptan delays paracetamol absorption in migraine patients. Clin Drug Invest. 1996;11(5):300-4.
5. Seaber EJ, Ridout G, Layton G, et al. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol. 1997;53(3-4):229-34.
6. Srinivasu P, Rambhua D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol. 2000;40:99-104.
7. Srinivas NR, Shyu WC, Upmalis D, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. J Clin Pharmacol. 1995;35(4):432-7.
8. Vachharajani NN, Shyu W-C, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Cephalalgia. 2002;22:282-7.
9. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine suffers. Br J Clin Pharmacol. 1983;166:95-699.
10. Veronese L, Gillotin C, Marion-Gallois R, et al. Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest. 1997;14:217-20.
11. Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug-drug interactions. Headache. 2002;42(Suppl 2):S63-73.
12. Tfelt-Hansen P, Rolan P. β-adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 519-28.
13. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol. 1991;32:581-4.
14. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90). Cephalalgia. 1997;17:21.
15. IB/ID agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol. 2001;52:69-76.
16. Fleishaker JC, Sisson TA, Carel BJ, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001;21:61-5.
17. electronic Medicines Compendium (eMC). Relpax 20 mg and 40 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/8195/SPC/RELPAX+20mg+and+40mg+Film- Coated+Tablets. [Accessed 2012 May 31].
18. Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia. 1991;11(Suppl. 11):228-9.
19. Seaber EJ, Gillotin C, Mohanlal R, et al. Lack of an interaction between pizotifen and the novel antimigraine compound zolmitriptan in healthy volunteers. Clin Drug Invest. 1997;14:221-5.
20. Van Hecken AM, Depré M, de Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol. 1992;34:82-4.
21. Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000;67:498-503.
22. MacLennan SJ, Martin GR. Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch Pharmacol. 1990;342(2):120-9.
23. Liston H, Bennett L, Usher B Jr, et al. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med. 1999;159(5):511-3.
24. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-20.
25. Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240268 patients. Headache. 2003;43:44-8.
26. Boutilier ASW, Gardner DM. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report. J Clin Pharm Ther. 2003;28:69-72.
27. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007;47:266-9.
28. Joffe RT, Sokolov STH. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand. 1997;95:551-2.
29. Smith DA, Cleary EW, Watkins S, et al. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36(6):301-5.
30. Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol. 2001;41:217-23.
31. Kempsford RD, Lacey LF, Thomas M, et al. The effect of alcohol on the pharmacokinetic profile of oral sumatriptan [abstract]. Fundam Clin Pharmacol. 1991;5:470.
32. electronic Medicines Compendium (eMC). Naramig tablets 2.5 mg: summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/759/SPC/Naramig+Tablets+2.5mg/ [Accessed 2012 Jun 06].
33. Shadle CR, Liu G, Goldberg MR. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J Clin Pharmacol. 2000;40(3):309-15.
34. Van Haarst AD, Van Gerven JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999;48(2):190-6.
35. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001;51:437-41.
36. Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol. 2003;43:423-7.
37. Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther. 2002;24(4):583-94.
38. Dixon R, French S, Kemp J, et al. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers. Clin Drug Investig. 1998;15(6):515-22.
39. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91(2):321-6.
40. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689-723.
41. Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46(1):57-63.
42. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur Neurol. 1991;31(5):300-5.
43. Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs. 2001;15(2):105-18.
44. GlaxoSmithKline. Clinical study register [online]. Available from URL: http://www.gsk-clinicalstudyregister.com/ [Accessed 2012 Aug 28].
45. Centre for Drug Evaluation and Research. Relpax: clinical pharmacology and biopharmaceutics review of original US submission [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21016-Relpax- BioPharmr.pdf [Accessed 2012 Aug 28].